We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this ...

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) were up 4.9% during mid-day trading on Friday . The company traded as high as $44.71 and last traded at $45.20. Approximately ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to CareSOUTH SAN FRANCISCO, Calif., ...

March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

Cytokinetics, Incorporated CYTK reported a net loss of $1.26 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter ...

In this article, we are going to look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...